Increased titers of neutralizing antibodies after immunization with both envelope proteins of the porcine endogenous retroviruses (PERVs)

Virology Journal

Volumn 9, Issue , 2012, Pages

  Denner, Joachim ^a   Mihica, Debora ^a   Kaulitz, Danny ^a   Schmidt, Christa Maria ^a  

^a ROBERT KOCH INSTITUTE   (Germany)

Author keywords

HIV 1; Neutralizing antibodies; Porcine Endogenous Retroviruses (PERV); Vaccine

Indexed keywords

ANTIGEN; ENVELOPE PROTEIN; EPITOPE; GLYCOPROTEIN; GLYCOPROTEIN GP 41; GLYCOPROTEIN GP 70; NEUTRALIZING ANTIBODY; TRANSMEMBRANE ENVELOPE PROTEIN P15E; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; BACTERIAL STRAIN; BLOOD SAMPLING; CELL MEMBRANE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; FUSION PEPTIDE PROXIMAL REGION; HAMSTER; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNIZATION; MEMBRANE PROXIMAL EXTERNAL REGION; NONHUMAN; NUCLEOTIDE SEQUENCE; PORCINE ENDOGENOUS RETROVIRUS; PROTEIN PURIFICATION; RETROVIRUS; RISK FACTOR; SEQUENCE HOMOLOGY; SEROLOGY; SWINE; VIRUS LOAD; VIRUS STRAIN; VIRUS TRANSCRIPTION; WESTERN BLOTTING; XENOTRANSPLANTATION;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CRICETINAE; ENDOGENOUS RETROVIRUSES; EPITOPES, B-LYMPHOCYTE; ESCHERICHIA COLI; HIV ENVELOPE PROTEIN GP41; SEQUENCE HOMOLOGY, AMINO ACID; SWINE; VACCINATION; VACCINES, SYNTHETIC; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES;

ANIMALIA; CRICETINAE; HUMAN IMMUNODEFICIENCY VIRUS 1; PORCINE ENDOGENOUS RETROVIRUS; SUIDAE;

EID: 84868233938     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-9-260     Document Type: Article

References (33)

1. Broad neutralization coverage of HIV by multiple highly potent antibodies. Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien JP, Wang SK, Ramos A, Chan-Hui PY, Moyle M, Mitcham JL, Hammond PW, Olsen OA, Phung P, Fling S, Wong CH, Phogat S, Wrin T, Simek MD, Koff WC, Wilson IA, Burton DR, Poignard P, Protocol G Principal Investigators, Nature 2011 477 466 470 10.1038/nature10373 21849977
2. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, Seaman MS, Zhou T, Schmidt SD, Wu L, Xu L, Longo NS, McKee K, O'Dell S, Louder MK, Wycuff DL, Feng Y, Nason M, Doria-Rose N, Connors M, Kwong PD, Roederer M, Wyatt RT, Nabel GJ, Mascola JR, Science 2010 329 856 861 10.1126/science.1187659 20616233
3. The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design. Montero M, van Houten NE, Wang X, Scott JK, Microbiol Mol Biol Rev 2008 72 54 84 10.1128/MMBR.00020-07 18322034 (Pubitemid 351398055)
4. Neutralizing antibodies against conserved domains of p15E of porcine endogenous retroviruses: basis for a vaccine for xenotransplantation? Fiebig U, Stephan O, Kurth R, Denner J, Virology 2003 307 406 413 10.1016/S0042-6822(02) 00140-X 12667808 (Pubitemid 36344171)
5. Neutralising antibodies against the transmembrane protein of feline leukaemia virus (FeLV). Langhammer S, Fiebig U, Kurth R, Denner J, Vaccine 2005 23 3341 3348 10.1016/j.vaccine.2005.01.091 15837241 (Pubitemid 40523129)
6. Antibodies neutralizing feline leukaemia virus (FeLV) in cats immunized with the transmembrane envelope protein p15E. Langhammer S, Hubner J, Kurth R, Denner J, Immunology 2006 117 229 237 10.1111/j.1365-2567.2005.02291.x 16423059
7. Increased neutralizing antibody response after simultaneous immunization with Leucogen and the feline leukemia virus transmembrane protein. Langhammer S, Fiebig U, Kurth R, Denner J, Intervirology 2010 54 78 86 20829603
8. Immunization with the transmembrane protein of a retrovirus, feline leukemia virus: absence of antigenemia following challenge. Langhammer S, Hübner J, Jarrett O, Kurth R, Denner J, Antiviral Res 2011 89 119 123 10.1016/j.antiviral.2010.11.011 21108970
9. Transspecies transmission of the endogenous koala retrovirus. Fiebig U, Hartmann MG, Bannert N, Kurth R, Denner J, J Virol 2006 80 5651 5654 10.1128/JVI.02597-05 16699047
10. Porcine endogenous retroviruses and xenotransplantation. Wilson CA, Cell Mol Life Sci 2008 65 3399 3412 10.1007/s00018-008-8498-z 18818871
11. Infection barriers to succesful xenbotransplantation focusing on porcine endogenous retroviruses. Denner J, Tönjes RR, Clin Microbiol Rev 2012 25 318 343 10.1128/CMR.05011-11 22491774
12. Generation of neutralising antibodies against porcine endogenous retroviruses (PERVs). Kaulitz D, Fiebig U, Eschricht M, Wurzbacher C, Kurth R, Denner J, Virology 2011 411 78 86 10.1016/j.virol.2010.12.032 21237477
13. Mode of interaction between the HIV-1 neutralizing monoclonal antibody 2F5 and its epitope. Fiebig U, Eschricht M, Schmolke M, Kurth R, Denner J, AIDS 2009 23 887 895 10.1097/QAD.0b013e3283292153 19414989
14. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. Zwick MB, Labrijn AF, Wang M, Spenlehauer C, Saphire EO, Binley JM, Moore JP, Stiegler G, Katinger H, Burton DR, Parren PW, J Virol 2001 75 10892 10905 10.1128/JVI.75.22.10892-10905.2001 11602729 (Pubitemid 33034579)
15. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. Muster T, Steindl F, Purtscher M, Trkola A, Klima A, Himmler G, Rüker F, Katinger H, J Virol 1993 67 6642 6647 7692082 (Pubitemid 23309131)
16. Towards an AIDS vaccine: the transmembrane envelope protein as target for broadly neutralizing antibodies. Denner J, Hum Vaccin 2011 7 4 9 10.4161/hv.7.0.14555 21266839
17. Induction of antibodies binding to the membrane proximal external region (MPER) of gp36 of HIV-2. Behrendt R, Fiebig U, Kurth R, Denner J, Intervirology 2012 55 252 256 10.1159/000324483 21454955
18. Immunological properties of the transmembrane envelope protein of the feline foamy virus and its use for serological screening. Mühle M, Bleiholder A, Kolb S, Hübner J, Löchelt M, Denner J, Virology 2011 412 333 340 10.1016/j.virol.2011.01.023 21316070
19. Functional links between the fusion peptide-proximal polar segment and membrane-proximal region of human immunodeficiency virus gp41 in distinct phases of membrane fusion. Bellamy-McIntyre AK, Lay CS, Baär S, Maerz AL, Talbo GH, Drummer HE, et al. J Biol Chem 2007 282 23104 23116 10.1074/jbc.M703485200 17526486 (Pubitemid 47311910)
20. The membrane proximal external region of the HIV-1 envelope glycoprotein gp41 contributes to the stabilization of the six-helix bundle formed with a matching N' peptide. Noah E, Biron Z, Naider F, Arshava B, Anglister J, Biochemistry 2008 47 6782 6792 10.1021/bi7023139 18540633 (Pubitemid 351898933)
21. Crystal structure of HIV-1 gp41 including both fusion peptide and membrane proximal external regions. Buzon V, Natrajan G, Schibli D, Campelo F, Kozlov MM, Weissenhorn W, PLoS Pathog 2010 6 1000880 10.1371/journal.ppat. 1000880 20463810
22. Genetic analysis of the rat leukemia virus: influence of viral sequences in transduction of the c-ras proto-oncogene and expression of its transforming activity. Lee SY, Howard TM, Rasheed S, J Virol 1998 72 9906 9917 9811727 (Pubitemid 28520857)
23. Transcriptional control of endogenous virus genes in murine lymphocytes. De Lamarter JF, Monckton RP, Moroni C, J Gen Virol 1981 52 371 375 10.1099/0022-1317-52-2-371 7288399 (Pubitemid 11133298)
24. Endogenous retrovirus expression in stimulated murine lymphocytes. Identification of a new locus controlling mitogen induction of a defective virus. Stoye JP, Moroni C, J Exp Med 1983 157 1660 1674 10.1084/jem.157.5.1660 6189943 (Pubitemid 13089004)
25. Activation of leukemia viruses by graft-versus-host and mixed lymphocyte reactions in vitro. Hirsch MS, Phillips SM, Solnik C, Black PH, Schwartz RS, Carpenter CB, Proc Natl Acad Sci USA 1972 69 1069 1072 10.1073/pnas.69.5.1069 4402535
26. Small virus-like particles in leukosis-like syndrome induced by certain antigens and immunostimulators. Denner J, Dorfman N, Acta Biol Med German 1977 36 1451 1458 616161 (Pubitemid 8361707)
27. Successful tumour immunotherapy: possible role of antibodies to anti-inflammatory factors produced by neoplasms. Nelson M, Nelson DS, Spradbrow PB, Kuchroo VK, Jennings PA, Cianciolo GJ, Snyderman R, Clin Exp Immunol 1985 61 109 117 4042416 (Pubitemid 15029855)
28. Expression of the human endogenous retrovirus-K transmembrane envelope, Rec and Np9 proteins in melanomas and melanoma cell lines. Büscher K, Hahn S, Hofmann M, Trefzer U, Ozel M, Sterry W, Löwer J, Löwer R, Kurth R, Denner J, Melanoma Res 2006 16 223 234 10.1097/01.cmr.0000215031.07941.ca 16718269 (Pubitemid 44085096)
29. Production of transgenic pigs that express porcine endogenous retrovirus small interfering RNAs. Ramsoondar J, Vaught T, Ball S, et al. Xenotransplantation 2009 16 164 180 10.1111/j.1399-3089.2009.00525.x 19566656
30. Long-term effects of PERV-specific RNA interference in transgenic pigs. Semaan M, Kaulitz D, Petersen B, Niemann H, Denner J, Xenotransplantation 2012 19 112 121 10.1111/j.1399-3089.2012.00683.x 22497513
31. Genetically-engineered subunit vaccine against feline leukaemia virus: protective immune response in cats. Marciani DJ, Kensil CR, Beltz GA, Hung CH, Cronier J, Aubert A, Vaccine 1991 9 89 96 10.1016/0264-410X(91)90262-5 1647576
32. Genetic alterations of the long terminal repeat of an ecotropic porcine endogenous retrovirus during passage in human cells. Denner J, Specke V, Thiesen U, Karlas A, Kurth R, Virology 2003 314 125 133 10.1016/S0042-6822(03)00428-8 14517066 (Pubitemid 37158012)
33. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Livak KJ, Schmittgen TD, Methods 2001 25 402 408 10.1006/meth.2001.1262 11846609 (Pubitemid 34164012)